All In Biotech

Drug Trial Radar · NCT00773513

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

A Randomized, Controlled, Open-Label, Multi-Centre, Parallel-Group Study To Assess All-Cause Mortality And Cardiovascular Morbidity In Patients With Chronic Kidney Disease On Dialysis And Those Not On Renal Replacement Therapy Under Treatment With MIRCERA® Or Reference ESAs.

Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,825 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,825

Actual

Start

Dec 12, 2008

Primary completion

Jul 27, 2017

Study completion Jul 27, 2017

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 16, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2 arm safety study will compare the outcome with respect to a composite endpoint of all-cause mortality and non-fatal cardiovascular events (myocardial infarction, stroke) in CKD participants either on dialysis or not receiving renal replacement therapy under treatment with methoxy polyethylene glycol-epoetin beta or reference ESAs. Participants will be randomized to receive intravenous (iv) or subcutaneous (sc) methoxy polyethylene glycol-epoetin beta at the following doses: for participants not already receiving ESA treatment, methoxy polyethylene glycol-epoetin beta will be administered at a starting dose of 0.6 micrograms per kilograms every 2 weeks (mcg/kg/2wks) iv or sc; for participants receiving maintenance ESA treatment, iv or sc methoxy polyethylene glycol-epoetin beta will be administered at an initial monthly dose of 120, 200 or 360 micrograms (mcg) depending on the weekly dose of ESA received prior to first methoxy polyethylene glycol-epoetin beta administration. Participants randomized to reference ESA treatment will receive iv or sc ESAs in accordance with their prescribed dosing information.

Conditions

  • Chronic Renal Anemia

Interventions

  • Darbepoetin AlfaDrug

    Darbepoetin alfa will be administered as per approved label.

  • Epoetin AlfaDrug

    Epoetin alfa will be administered as per approved label.

  • Epoetin BetaDrug

    Epoetin beta will be administered as per approved label.

  • methoxy polyethylene glycol-epoetin betaDrug

    Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred FirstTime frame: Baseline up to approximately 8.5 years

Locations

196 sites in 27 countries. Site status is shown where the registry gives one.

  • Fresenius Medical Care Martinez

    Buenos Aires, Argentina

  • Fresenius Medical Care Morón

    Buenos Aires, Argentina

  • Fresenius Medical Care San Martin

    Buenos Aires, Argentina

  • Fresenuis Medical Care Mansilla

    CABA, Argentina

  • Gosford Hospital; Renal

    Gosford, New South Wales, Australia

  • Renal Research Dr Simon Roger

    Gosford, New South Wales, Australia

  • Cairns Hospital; Renal Services

    Cairns, Queensland, Australia

  • Gold Coast Hospital Department of Pharmacology & Therapeutics

    Southport, Queensland, Australia

  • ROYAL ADELAIDE HOSPITAL; Renal Clinical Trials, CNARTS

    Adelaide, South Australia, Australia

  • Launceston General Hospital; Diabetes and Renal Research Unit

    Launceston, Tasmania, Australia

  • Monash Medical Centre; Renal Transplant Unit

    Clayton, Victoria, Australia

  • Royal Perth Hospital; Nephrology

    Perth, Western Australia, Australia

  • UZ Brussel

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • AZ Delta (Campus Wilgenstraat)

    Roeselare, Belgium

  • Centro Mineiro de Pesquisa - CMIP

    Juiz de Fora, Minas Gerais, Brazil

  • PUCPR

    Curitiba, Paraná, Brazil

  • Hospital Univ. Pedro Ernesto - Hupe; Nefrologia

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, São Paulo, Brazil

  • Universidade Federal de Sao Paulo - UNIFESP

    São Paulo, São Paulo, Brazil

  • Clinica de Medicina Interna e Nefrologia (CMIN)

    São Paulo, São Paulo, Brazil

  • Hospital das Clinicas - FMUSP; Nefrologia

    São Paulo, São Paulo, Brazil

  • Instituto de Hemodialise Sorocaba

    Sorocaba, São Paulo, Brazil

  • General Hospital Karlovac; Dept of Haemodialysis

    Karlovac, Croatia

  • Clinical Hospital Osijek; Dept of Haemodialysis

    Osijek, Croatia

  • Clinical Hospital Center Rijeka; Dialysis

    Rijeka, Croatia

  • General Hospital Josip Bencevic; Department of Haemodialysis

    Slavonski Brod, Croatia

  • Clinical Hospital Split; Dialysis

    Split, Croatia

  • General Hospital Zadar; Dialysis

    Zadar, Croatia

  • Klinicki Bolnicki Centar Zagreb; Dialysis

    Zagreb, Croatia

  • Fakultni Nemocnice Kralovske Vinohrady (FNKV); Interni Hematologicka Klinika

    Hradec Králové, Czechia

  • Faculty Hospital; Dialysis Unit

    Ostrava, Czechia

  • Institut Klinicke A Experimentalni Mediciny Klinika Nefrologie

    Prague, Czechia

  • Nemocnice Strahov; Interni Oddeleni-Strahov

    Prague, Czechia

  • Centre Hospitalier; Hemodialyse

    Annonay, France

  • Hopital Pellegrin; Departement Nephrologie

    Bordeaux, France

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.